Category: Private Citizen — Corporate Director Role: Independent Director, Microsoft Corporation (MSFT) Board Tenure: 2019 – present Committee Memberships: Compensation Committee; Environmental, Social, and Public Policy (ESPP) Committee Profile Type: Board Member Accountability — Anchor B (Documented Organizational Leadership)

Basis for Inclusion: Emma N. Walmsley holds a documented governance role as an independent director of Microsoft Corporation, which made documented political donations to Trump-aligned entities while the corporation faced regulatory and policy decisions directly affecting its financial interests. Walmsley’s concurrent role as CEO of GSK plc — a global pharmaceutical company subject to FDA oversight and U.S. healthcare policy decisions — creates a governance profile of cross-sector significance. This profile documents the factual governance relationship, not the subject’s personal political views.

Subject Classification: Private Citizen / Corporate Director. Board membership is a matter of public record (SEC filings, proxy statements). This profile documents only the governance role and its connection to documented corporate political activity.

What is NOT the basis for inclusion: Walmsley’s personal political opinions, party affiliation, public statements, or any protected speech are NOT the basis for inclusion. The basis is solely the documented directorial role and its fiduciary connection to corporate political spending documented in the parent corporate donor profile.

Biographical Overview

Emma N. Walmsley has been CEO and a director of GSK plc (formerly GlaxoSmithKline), one of the world’s largest pharmaceutical companies, since 2017. She was the first woman to lead a major pharmaceutical company of GSK’s scale and is widely regarded as one of the most influential executives in global healthcare. Before becoming CEO, she led GSK’s Consumer Healthcare division. Prior to GSK, she spent 17 years at L’Oréal in senior leadership roles in the UK, U.S., and China.

As CEO of GSK, Walmsley oversees a company with annual revenues of approximately £30 billion and a portfolio of vaccines, specialty medicines, and general medicines. GSK’s commercial and research interests are directly affected by U.S. regulatory and reimbursement policy, FDA approval processes, and healthcare legislation — areas where Trump administration policy decisions have significant financial consequences for the company.

She holds a B.A. in Classics and Modern Languages from Oxford University.

Board Role and Governance Authority

• Company: Microsoft Corporation (NASDAQ: MSFT)
• Board tenure: 2019 – present
• Committee assignments: Compensation Committee; Environmental, Social, and Public Policy (ESPP) Committee
• Day job: CEO & Director, GSK plc (LSE/NYSE: GSK)

Other Current Board Memberships

• Director, GSK plc (NYSE: GSK) — in executive capacity as CEO

Parent Corporate Donor Profile

This profile is a governance-accountability companion to the Microsoft — Corporate Donor Profile, which documents the corporation’s political spending, pending government business, and favorable outcomes under the Trump administration.

Factual correction requests: If you believe information in this profile is incorrect, please contact factcheck@patriot.university with your name (optional), the specific claim, and any supporting documentation. We review all submissions and correct verified errors promptly.

Sources

• Microsoft Corporation DEF 14A Proxy Statement, filed October 21, 2025 (annual meeting December 5, 2025)
• SEC EDGAR filing: Microsoft Corporation (CIK 789019)